CD19 and neoplasm: Taking the concept of multitargeting introduced with bispecific antibodies a step further, trispecific antibodies are at an early stage of investigation, with PIT565 demonstrating simultaneous engagement of CD19 on tumor cells, CD3 and CD2 on T cells leading to redirected T‐cell cytotoxicity toward CD19+ malignant B cells.